{"id":862,"date":"2026-05-25T03:49:51","date_gmt":"2026-05-25T03:49:51","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&p=862"},"modified":"2026-07-07T09:12:26","modified_gmt":"2026-07-07T09:12:26","slug":"cjc-1295-ghrp-2-blend-10mg","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/cjc-1295-ghrp-2-blend-10mg\/","title":{"rendered":"CJC-1295 & GHRP-2 Blend (10mg)"},"content":{"rendered":"

CJC-1295 & GHRP-2 Blend (10mg): A Dual\u2011Pathway Synergistic Tool for Growth Hormone Research<\/span><\/h1>\n

If your research explores the hypothalamic-pituitary-somatotropic axis, the dynamics of growth hormone (GH) secretion, or the downstream effects of insulin-like growth factor 1 (IGF-1), the\u00a0<\/span>CJC-1295 & GHRP-2 Blend (10mg) research peptide<\/span><\/strong>\u00a0offers a precisely defined, dual\u2011pathway experimental platform. This 10\u202fmg formulation combines two mechanistically distinct yet complementary GH secretagogues\u2014<\/span>CJC-1295 (Mod GRF 1-29)<\/span><\/strong>, a modified, long\u2011acting analogue of growth hormone\u2011releasing hormone (GHRH), and\u00a0<\/span>GHRP-2<\/span><\/strong>\u00a0(Pralmorelin), a potent ghrelin receptor agonist. <\/span><\/p>\n

By simultaneously targeting the GHRH receptor and the growth hormone secretagogue receptor (GHS\u2011R1a), this blend allows researchers to model the synergistic interplay between sustained baseline stimulation and pulsatile bursts, providing deeper insight into the regulatory circuits that govern GH pulsatility and IGF\u20111 signalling<\/span>.<\/span><\/p>\n

At\u00a0<\/span>Wuhan Top Miracle Peptides<\/span><\/strong>, we supply high\u2011purity\u00a0<\/span>CJC-1295 & GHRP-2 Blend (10mg) research peptide<\/span><\/strong>\u00a0to research institutions and wholesale buyers across the\u00a0<\/span>United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA<\/span><\/strong>. Every batch is lyophilised, HPLC\u2011verified to \u226598% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation, IGF\u20111 signalling, and metabolic research begin with uncompromising quality.<\/span><\/p>\n

What Is the CJC-1295 & GHRP\u20112 Blend and How Does It Work?<\/span><\/h2>\n

To fully appreciate the research potential of the\u00a0<\/span>CJC-1295 & GHRP-2 Blend (10mg) research peptide<\/span><\/strong>, it is essential to understand the distinct yet complementary mechanisms of its two components. Each peptide exploits a separate G\u2011protein\u2011coupled receptor (GPCR) with divergent downstream signalling, yet both ultimately converge on the somatotroph’s secretory machinery<\/span>.<\/span><\/p>\n

CJC-1295 (Mod GRF 1-29): The Long\u2011Acting GHRH Analog<\/span><\/h3>\n

CJC\u20111295 is a synthetic peptide derivative of growth hormone\u2011releasing hormone (GHRH), specifically a tetrasubstituted analogue of the N\u2011terminal 29 amino acids of hGRF(1\u201129)<\/span>. Unlike CJC\u20111295\u2011DAC, which contains a drug affinity complex (DAC) moiety and has an extended half\u2011life of approximately 8 days, the version in this blend\u2014CJC\u20111295 without DAC (also called Modified GRF 1\u201129)\u2014does not contain the DAC moiety<\/span>. However, it still features four amino acid substitutions that enhance its stability and resistance to proteolytic degradation, including a D\u2011alanine substitution at the 2\u2011position that resists enzymatic degradation by dipeptidylpeptidase\u2011IV (DPP\u2011IV)<\/span>.<\/span><\/p>\n

As a GHRH analogue, CJC\u20111295 binds to GHRH receptors on pituitary somatotrophs, stimulating the synthesis and release of growth hormone<\/span>. Studies have reported that administering CJC\u20111295 can increase plasma GH concentrations\u00a0<\/span>2\u201110 times more<\/span><\/strong>\u00a0for a period of up to 6 days after injection<\/span>. The version without DAC creates GH pulses that closely mimic natural physiology, supporting a more pulsatile release pattern<\/span>. CJC\u20111295 has shown a\u00a0<\/span>4\u2011fold increase in GH area under the curve<\/span><\/strong>\u00a0over a 2\u2011hour period compared with native hGRF(1\u201129)<\/span>.<\/span><\/p>\n

GHRP-2 (Pralmorelin): The Potent Ghrelin Receptor Agonist<\/span><\/h3>\n

GHRP\u20112 (Growth Hormone Releasing Peptide\u20112, also known as Pralmorelin or KP\u2011102) is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) class<\/span>. It acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS\u2011R1a), a GPCR expressed in the hypothalamus and pituitary<\/span>.<\/span><\/p>\n

GHRP\u20112 triggers GH release through several pathways, including calcium channel modulation, cAMP pathway activation, and protein kinase C signalling<\/span>. It has been shown to stimulate GH release from rat pituitary cells via the same receptor and mechanism as GHRP\u20116, despite structural differences between the peptides<\/span>. GHRP\u20112 is known for its robust, dose\u2011dependent GH\u2011releasing activity. A characteristic feature is that its effect is\u00a0<\/span>synergistic with GHRH<\/span><\/strong>.<\/span><\/p>\n

Mechanism of Synergy: Sustained Stimulation Meets Pulsatile Amplification<\/span><\/h3>\n

The scientific rationale for combining CJC\u20111295 and GHRP\u20112 lies in their convergent yet distinct mechanisms<\/span>. When conceptualised as a blended research framework, these peptides invite investigation into how their complementary properties might interact<\/span>:<\/span><\/p>\n